Literature DB >> 7597312

Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis.

A van Elsas1, S Zerp, S van der Flier, M Krüse-Wolters, A Vacca, D J Ruiter, P Schrier.   

Abstract

Determination of the activation state of oncogenes as well as tumor suppressor genes is a main subject of interest in the analysis of the mechanism of tumor initiation. In human melanoma, the c-myc and N-ras oncogenes have been found to be activated in approximately 50% and 15% of the analyzed material, respectively. These studies have mostly been done on fresh tumor material or cell lines. Only in a few cases has an attempt been made to look at tumor heterogeneity or clonality with respect to the activation of oncogenes. We have adjusted the polymerase chain reaction (PCR)/single-stranded conformation polymorphism analysis (SSCP) technique to screen paraffin-embedded melanoma material for the presence of N-ras mutations and found genetic defects at particular progression stages. In one melanoma of the skin, we were able to sublocalize an N-ras mutation in the intraepidermal tumor part, that was absent in the part deeply invading the dermal layer. We conclude that a thorough investigation of N-ras activation in human melanoma should include analysis of histologically different parts of the tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7597312     DOI: 10.1007/978-3-642-78771-3_5

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  9 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Novel Ras antagonist blocks human melanoma growth.

Authors:  B Jansen; H Schlagbauer-Wadl; H Kahr; E Heere-Ress; B X Mayer; H Eichler; H Pehamberger; M Gana-Weisz; E Ben-David; Y Kloog; K Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 3.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.

Authors:  Holly S Greenwald; Erica B Friedman; Iman Osman
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

Review 4.  Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma.

Authors:  Joshua X Wang; Mizuho Fukunaga-Kalabis; Meenhard Herlyn
Journal:  J Cell Commun Signal       Date:  2016-08-23       Impact factor: 5.782

5.  Episodic Src activation in uveal melanoma revealed by kinase activity profiling.

Authors:  W Maat; M el Filali; A Dirks-Mulder; G P M Luyten; N A Gruis; L Desjardins; P Boender; M J Jager; P A van der Velden
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

Review 6.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

7.  Targeted agents for the treatment of metastatic melanoma.

Authors:  Jose G Monzon; Janet Dancey
Journal:  Onco Targets Ther       Date:  2012-03-05       Impact factor: 4.147

8.  RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma.

Authors:  Dazhi Yang; Juan Tao; Luowei Li; Noemi Kedei; Zsuzsanna E Tóth; Alexandra Czap; Julia F Velasquez; Daniela Mihova; Aleksandra M Michalowski; Stuart H Yuspa; Peter M Blumberg
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

Review 9.  Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).

Authors:  Antoni Xavier Torres-Collado; Jeffrey Knott; Ali R Jazirehi
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.